C4 Therapeutics CCCC 深 沪
已收盘 10-17 16:00:00 美东时间
2.37
-0.110
-4.44%
华盛通- 最 高2.5199
- 今 开2.46
- 成交量 248.96万股
- 最 低 2.315
- 昨 收 2.48
- 总市值 1.69亿
- 52周最高 6.52
- 市盈率 静 --
- 换手率 3.50%
- 52周最低 1.085
- 委 比 98.88%
- 总股本 7117.08万
- 历史最高 51.21
- 量 比 0.68
- 振 幅 8.26%
- 历史最低 1.06
- 每 手 1
- 风险率 2.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Precision Oncology Approaches Drive $312B Market Transformation
USA News Group News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates ...
10-17 21:00
美股牛股 | PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；生物技术股WHWK涨超24%
PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；WHWK涨超24%，与Tempus AI建立战略伙伴关系，共同推进肿瘤研究领域发展>>
10-17 17:43
C4 Therapeutics prices $125M equity offering with warrants
C4 Therapeutics (NASDAQ:CCCC) priced an offering of 21.9M shares and 28.7M pre-funded warrants, each paired with Class A and Class B Warrants. Securities priced at $2.47/share or $2.4699/pre-funded wa...
10-16 19:27
C4 Therapeutics Presents Phase 1 Trial Data
An announcement from C4 Therapeutics ( ($CCCC) ) is now available. On October 1...
10-16 18:58
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
C4 Therapeutics announced the pricing of an underwritten offering to institutional investors, raising $125 million to fund the next phase of cemsidomide development in treating multiple myeloma, including a Phase 2 registrational trial with dexamethasone and a Phase 1b trial with elranatamab. The offering, led by RA Capital Management, includes shares of common stock and pre-funded warrants, with potential for an additional $225 million if all wa...
10-16 11:08
C4 Therapeutics Partners with Pfizer for Clinical Trial
The latest announcement is out from C4 Therapeutics ( ($CCCC) ). On October 1, ...
10-01 19:28
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
C4 Therapeutics (C4T) has entered into a clinical trial collaboration with Pfizer, where Pfizer will supply elranatamab for C4T's upcoming Phase 1b trial. The trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, in combination with elranatamab and dexamethasone for treating multiple myeloma. Initiated in Q2 2026, the trial aims to determine the optimal dose of cemsidomide. C4T hopes the collaboration will lead to a...
10-01 11:00
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10
Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from $5 to $10.
09-23 20:43
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
